Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
Titel:
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
Auteur:
Pistilli, B. Pluard, T. Urruticoechea, A. Farci, D. Kong, A. Bachelot, T. Chan, S. Han, H. S. Jerusalem, G. Urban, P. Robinson, D. Mouhaër, S. L. Tomaso, E. D. Massacesi, C. Saura, C.